Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024
22 juil. 2024 16h05 HE
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares – June 2024
22 juil. 2024 16h05 HE
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
22 juil. 2024 06h30 HE
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
18 juil. 2024 07h30 HE
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA®
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
17 juil. 2024 18h45 HE
|
Nufarm
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina.
Industrial Roboverse in F&B and Pharmaceutical Markets, 2024 Research - Opportunities in Collaborative Robots, Warehouse Automation, and AI-driven Robots
17 juil. 2024 05h36 HE
|
Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Industrial Roboverse Growth Opportunities in the F&B and Pharmaceutical Industries" report has been added to ResearchAndMarkets.com's...
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
16 juil. 2024 16h01 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Lynch Carpenter Investigates Claims in Rite Aid Data Breach
16 juil. 2024 14h57 HE
|
Lynch Carpenter
PITTSBURGH, July 16, 2024 (GLOBE NEWSWIRE) -- Rite Aid Corporation (“Rite Aid”) recently announced that it suffered from a data breach which impacted the personal information of approximately 2.2...
萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.